GSK (NYSE:GSK) Stock Passes Above 200 Day Moving Average – What’s Next?

GSK PLC Sponsored ADR (NYSE:GSK) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $48.94 and traded as high as $52.69. GSK shares last traded at $51.9540, with a volume of 4,333,574 shares traded.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. HSBC restated a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. TD Cowen reissued a “hold” rating on shares of GSK in a research report on Monday, February 9th. Weiss Ratings lowered shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research report on Friday, January 16th. Finally, Wall Street Zen cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $44.13.

GSK Trading Up 3.3%

The firm has a 50-day moving average of $54.88 and a 200 day moving average of $49.07. The company has a market cap of $111.40 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 3.20 and a beta of 0.44. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.92.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 9th. Stockholders of record on Friday, February 20th will be given a dividend of $0.4856 per share. This is a positive change from GSK’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, February 20th. This represents a $1.94 annualized dividend and a dividend yield of 3.6%. GSK’s payout ratio is 51.62%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Twin Peaks Wealth Advisors LLC bought a new stake in shares of GSK during the second quarter worth about $25,000. First Horizon Corp lifted its position in GSK by 78.7% in the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 236 shares in the last quarter. Elyxium Wealth LLC acquired a new position in GSK during the 4th quarter valued at about $30,000. CNB Bank bought a new stake in GSK during the 3rd quarter worth approximately $31,000. Finally, CoreFirst Bank & Trust bought a new stake in GSK during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.